ArticleCancer medicine2026
A Real-World Experience of Prognostic Factors of Survival Outcomes in a Taiwanese Population With Unresectable Hepatocellular Carcinoma Treated With First-Line Lenvatinib.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLenvatinib is approved as a first-line treatment for unresectable hepatocellular carcinoma (HCC), but real-world outcomes may vary due to patient heterogeneity. This study aimed to evaluate the real-world efficacy of lenvatinib in Taiwanese patients and to identify prognostic factors influencing outcomes.
methodsThis retrospective cohort study included 111 patients with unresectable HCC treated with the first-line lenvatinib between February 2020 and April 2023 at Taichung Veterans General Hospital. All patients were Child-Pugh class A and had at least one measurable lesion per mRECIST. Radiological tumor response, overall survival (OS), and progression-free survival (PFS) were recorded and analyzed.
resultsThe ORR and DCR were 36% and 81% respectively. The median OS of all patients was 17 months, and PFS was 10 months. Patients with ALBI grade 1 (HR 0.45, 95% CI 0.24-0.84, p = 0.011) and receiving combined locoregional therapy (LRT) (HR 0.38, 95% CI 0.20-0.79, p = 0.003) had significantly longer OS. AFP ≤ 400 ng/mL was associated with longer PFS (HR 0.35, 95% CI 0.35-0.94, p = 0.028).
conclusionLenvatinib is effective in real-world treatment of unresectable HCC, especially when combined with LRT. ALBI grade 1 and AFP ≤ 400 ng/mL are favorable prognostic indicators for survival and disease control. These findings support personalized treatment strategies and warrant further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.